• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Betaxon

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Betaxon

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Betaxon (levobetaxolol hydrochloride suspension, drops) is an ophthalmic suspension which, when instilled in the eye, reduces intraocular pressure (IOP), a major risk factor in glaucomatous field loss. Elevated IOP accounts for greater likelihood of optic nerve damage and visual field loss. Most of the diseases of the eye which cause glaucoma are characterized by increased IOP.

    Currently, there is no cure for glaucoma. Furthermore, since there are no obvious symptoms, it is difficult to detect glaucoma before serious loss of sight is experienced. The best defense is to have regular eye exams. See below for a list of populations that are of higher risk for developing glaucoma.

    Clinical Results

    In two clinical research studies in which a total of 365 patients were dosed for three months with the study drug, Betaxon was shown to significantly reduce IOP at all follow up visits.

    Side Effects

    The main adverse effects experienced by patients in clinical trials included:

    • Discomfort of the eye upon treatment
    • Blurred vision
    • Cataracts and vitreous disorders (experienced by less than 2% of the patients)

    In addition, the same adverse reactions that may occur with systemic beta-adrenergic blocking agents may result from this topically applied beta-adrenergic blocking agent. These effects may include:

    • Severe respiratory reactions
    • Severe cardiac reactions

    Betaxon is contraindicated in patients with sinus bradycardia, greater than a first degree atrioventricular block, cardiogenic shock, or patients with over cardiac failure.

    Results of clinical research indicate that this drug may have a minor effect on heart rate and blood pressure.

    Mechanism of Action

    Since racemic betaxolol and other beta-adrenergic antagonists have been shown to reduce intraocular pressure by a reduction of aqueous production as demonstrated by tonography and aqueous flourophotometry, it is assumed that the mechanism of action of levobetaxolol is similar. The intraocular lowering effect of racemic betaxolol can generally be noted within 30 minutes and the maximal effect can usually be detected two hours after topical administration. It is assumed that the intraocular lowering time profile of levobetaxolol is similar. A single dose provides approximately a 12-hour reduction in intraocular pressure. (FDA Label)

    Literature References

    To learn more about the eye disorder, glaucoma, and research being done in this field, visit the Glaucoma Foundation web site: www.glaucoma-foundation.org

    Alcon Laboratories, Inc., the company that produces Betaxon, is an eyecare resource for both consumers and professionals. Visit the Alcon Labs web site: www.alconlabs.com

    Additional Information

    According to the Glaucoma Foundation, you may be at greater risk for developing the glaucoma if:

    • you are over 45 and have not had your eyes examined regularly
    • someone in your family has a history of glaucoma
    • you have abnormally high intraocular pressure
    • you are of African descent
    • you have diabetes
    • you are myopic (nearsighted)
    • you have had regular, long-term steroid/cortisone use
    • you have had previous eye injury
    Approval Date: 2000-02-01
    Company Name: Alcon
    Back to Listings

    Upcoming Events

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • Resources-360x240.png

      Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

    • FocusinRed-360x240.png

      Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

    • VaccinewithNeedle-360x240.png

      2021 Vaccine Industry Will Continue to be Dominated by COVID-19 Trials, Experts Say

    • Dominate-360x240.png

      COVID-19, Oncology, CNS and Infectious Disease Trials Will Dominate in 2021, Survey Predicts

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing